These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2737222)

  • 1. Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients.
    Osterborg A; Ehrsson H; Eksborg S; Wallin I; Mellstedt H
    Eur J Cancer Clin Oncol; 1989 May; 25(5):899-903. PubMed ID: 2737222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma.
    Sirohi B; Powles R; Kulkarni S; Rudin C; Saso R; Rigg A; Horton C; Singhal S; Mehta J; Treleaven J
    Br J Cancer; 2001 Aug; 85(3):325-32. PubMed ID: 11487259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal function in the elimination of oral melphalan in patients with multiple myeloma.
    Adair CG; Bridges JM; Desai ZR
    Cancer Chemother Pharmacol; 1986; 17(2):185-8. PubMed ID: 3719900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan.
    Tamaki M; Nakasone H; Gomyo A; Hayakawa J; Akahoshi Y; Harada N; Kusuda M; Ishihara Y; Kawamura K; Tanihara A; Sato M; Terasako-Saito K; Kameda K; Wada H; Kikuchi M; Kimura SI; Kako S; Kanda Y
    Int J Hematol; 2018 Oct; 108(4):423-431. PubMed ID: 30039440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma.
    Ehrsson H; Eksborg S; Osterborg A; Mellstedt H; Lindfors A
    Med Oncol Tumor Pharmacother; 1989; 6(2):151-4. PubMed ID: 2747308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment.
    Carlson K; Hjorth M; Knudsen LM;
    Br J Haematol; 2005 Mar; 128(5):631-5. PubMed ID: 15725084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral melphalan pharmacokinetics: influence of interferon-induced fever.
    Ehrsson H; Eksborg S; Wallin I; Osterborg A; Mellstedt H
    Clin Pharmacol Ther; 1990 Jan; 47(1):86-90. PubMed ID: 2295223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival.
    Carlson K
    Bone Marrow Transplant; 2005 May; 35(10):985-90. PubMed ID: 15806125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of high-dose melphalan in adults: influence of renal function.
    Kergueris MF; Milpied N; Moreau P; Harousseau JL; Larousse C
    Anticancer Res; 1994; 14(6A):2379-82. PubMed ID: 7825976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.
    Loos U; Musch E; Engel M; Hartlapp JH; Hügl E; Dengler HJ
    Eur J Clin Pharmacol; 1988; 35(2):187-93. PubMed ID: 3191937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment.
    Song MK; Chung JS; Shin HJ; Moon JH; Lee JJ; Yoon SS; Kim JS; Lee JO; Do YR; Lee HS; Park EK;
    Ann Hematol; 2012 Jun; 91(6):889-96. PubMed ID: 22237937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.
    Tricot G; Alberts DS; Johnson C; Roe DJ; Dorr RT; Bracy D; Vesole DH; Jagannath S; Meyers R; Barlogie B
    Clin Cancer Res; 1996 Jun; 2(6):947-52. PubMed ID: 9816255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma.
    Taha IA; Ahmad RA; Gray H; Roberts CI; Rogers HJ
    Cancer Chemother Pharmacol; 1982; 9(1):57-60. PubMed ID: 7139852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
    Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.
    Nath CE; Shaw PJ; Trotman J; Zeng L; Duffull SB; Hegarty G; McLachlan AJ; Gurney H; Kerridge I; Kwan YL; Presgrave P; Tiley C; Joshua D; Earl J
    Br J Clin Pharmacol; 2010 May; 69(5):484-97. PubMed ID: 20573084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of cimetidine with oral melphalan. A pharmacokinetic study.
    Sviland L; Robinson A; Proctor SJ; Bateman DN
    Cancer Chemother Pharmacol; 1987; 20(2):173-5. PubMed ID: 3311444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melphalan hydrochloride for the treatment of multiple myeloma.
    Esma F; Salvini M; Troia R; Boccadoro M; Larocca A; Pautasso C
    Expert Opin Pharmacother; 2017 Aug; 18(11):1127-1136. PubMed ID: 28658983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of multiple myeloma: renal function in relation to its prognosis].
    Akashi M; Ohta M; Kitagawa S; Furukawa Y; Takeda K; Muroi K; Komatsu N; Ikeda K; Ohsaka A; Yoshida M
    Rinsho Ketsueki; 1988 Nov; 29(11):1991-7. PubMed ID: 3236408
    [No Abstract]   [Full Text] [Related]  

  • 19. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
    Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
    J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
    Dimopoulos MA; Richardson PG; Schlag R; Khuageva NK; Shpilberg O; Kastritis E; Kropff M; Petrucci MT; Delforge M; Alexeeva J; Schots R; Masszi T; Mateos MV; Deraedt W; Liu K; Cakana A; van de Velde H; San Miguel JF
    J Clin Oncol; 2009 Dec; 27(36):6086-93. PubMed ID: 19858394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.